株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

原発性免疫不全症 (PID) : パイプライン分析

Primary Immune Deficiency (PID) - Pipeline Review, H2 2019

発行 Global Markets Direct 商品コード 229789
出版日 ページ情報 英文 104 Pages
即納可能
価格
本日の銀行送金レート: 1USD=111.33円で換算しております。
Back to Top
原発性免疫不全症 (PID) : パイプライン分析 Primary Immune Deficiency (PID) - Pipeline Review, H2 2019
出版日: 2019年11月25日 ページ情報: 英文 104 Pages
概要

原発性免疫不全症 (PID)は、弱まった免疫機構と定義されており、繰り返し感染症を引き起こし、その他の健康障害も発生しやすくなります。症候は、血液感染症、肺炎、気管支炎、副鼻腔感染症、耳感染症、髄膜炎、皮膚感染症、けいれん、食欲不振、吐き気や下痢などの消化器官障害があります。

当レポートでは、原発性免疫不全症 (PID)の治療薬開発パイプラインの現況と最新アップデートによる各開発段階の比較分析、企業や研究機関によって開発中の治療薬、治療薬の評価、後期段階および中止されたプロジェクトに関する情報などを最新のニュースや発表も交えて提供しています。

イントロダクション

  • 調査範囲

原発性免疫不全症 (PID) 概要

治療薬の開発

  • パイプライン製品;概要
  • パイプライン製品;比較分析

企業で開発中の治療薬

大学/機関で研究中の治療薬

パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品

企業で開発中の製品

大学/機関で研究中の製品

治療薬開発に従事している企業

  • ADMA Biologics, Inc.
  • Baxter International Inc.
  • Genethon
  • GlaxoSmithKline plc
  • Green Cross Corporation
  • ProMetic Life Sciences Inc.
  • Sangamo BioSciences, Inc.
  • Sanofi

治療薬の評価

  • 単剤製品
  • 併用製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

  • (immune globulin (human) + hyaluronidase (recombinant))
  • GC-1112
  • Gene Therapy for Severe Combined Immune Deficiency
  • Gene Therapy for X-Linked SCID
  • Gene Therapy to Activate Artemis for Radiosensitive Severe Combined Immunodeficiency
  • GSK-2696273
  • immune globulin (human)
  • immune globulin (human)
  • OT-81
  • plerixafor
  • RI-002
  • Stem Cell Therapy to Activate Adenosine Deaminase for Severe Combined Immune Deficiency
  • Stem Cell Therapy to Activate Adenosine Deaminase for Severe Combined Immune Deficiency
  • Stem Cell Therapy to Activate IL-2 Gamma Receptor for SCID-X1

最近のパイプライン動向

休止中のプロジェクト

製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

図表

図表

List of Tables

  • Table 1: Number of Products under Development for Primary Immune Deficiency (PID), H2 2019
  • Table 2: Number of Products under Development by Companies, H2 2019
  • Table 3: Number of Products under Development by Universities/Institutes, H2 2019
  • Table 4: Products under Development by Companies, H2 2019
  • Table 5: Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Table 6: Products under Development by Universities/Institutes, H2 2019
  • Table 7: Number of Products by Stage and Target, H2 2019
  • Table 8: Number of Products by Stage and Mechanism of Action, H2 2019
  • Table 9: Number of Products by Stage and Route of Administration, H2 2019
  • Table 10: Number of Products by Stage and Molecule Type, H2 2019
  • Table 11: Primary Immune Deficiency (PID) - Pipeline by ADMA Biologics Inc, H2 2019
  • Table 12: Primary Immune Deficiency (PID) - Pipeline by AlloVir Inc, H2 2019
  • Table 13: Primary Immune Deficiency (PID) - Pipeline by Biotest AG, H2 2019
  • Table 14: Primary Immune Deficiency (PID) - Pipeline by Cellective BioTherapy Inc, H2 2019
  • Table 15: Primary Immune Deficiency (PID) - Pipeline by Clinigen Group Plc, H2 2019
  • Table 16: Primary Immune Deficiency (PID) - Pipeline by Enzyvant Sciences Ltd, H2 2019
  • Table 17: Primary Immune Deficiency (PID) - Pipeline by Evolve Biologics Inc, H2 2019
  • Table 18: Primary Immune Deficiency (PID) - Pipeline by GC Pharma, H2 2019
  • Table 19: Primary Immune Deficiency (PID) - Pipeline by GigaGen Inc, H2 2019
  • Table 20: Primary Immune Deficiency (PID) - Pipeline by Grifols SA, H2 2019
  • Table 21: Primary Immune Deficiency (PID) - Pipeline by Liminal BioSciences Inc, H2 2019
  • Table 22: Primary Immune Deficiency (PID) - Pipeline by Mustang Bio Inc, H2 2019
  • Table 23: Primary Immune Deficiency (PID) - Pipeline by Octapharma AG, H2 2019
  • Table 24: Primary Immune Deficiency (PID) - Pipeline by Orchard Therapeutics Plc, H2 2019
  • Table 25: Primary Immune Deficiency (PID) - Pipeline by Rocket Pharmaceuticals Inc, H2 2019
  • Table 26: Primary Immune Deficiency (PID) - Pipeline by Sangamo Therapeutics Inc, H2 2019
  • Table 27: Primary Immune Deficiency (PID) - Pipeline by Taiga Biotechnologies Inc, H2 2019
  • Table 28: Primary Immune Deficiency (PID) - Pipeline by Takeda Pharmaceutical Co Ltd, H2 2019
  • Table 29: Primary Immune Deficiency (PID) - Pipeline by X4 Pharmaceuticals Inc, H2 2019
  • Table 30: Primary Immune Deficiency (PID) - Dormant Projects, H2 2019
  • Table 31: Primary Immune Deficiency (PID) - Discontinued Products, H2 2019

List of Figures

  • Figure 1: Number of Products under Development for Primary Immune Deficiency (PID), H2 2019
  • Figure 2: Number of Products under Development by Companies, H2 2019
  • Figure 3: Number of Products under Development by Universities/Institutes, H2 2019
  • Figure 4: Number of Products by Targets, H2 2019
  • Figure 5: Number of Products by Stage and Targets, H2 2019
  • Figure 6: Number of Products by Mechanism of Actions, H2 2019
  • Figure 7: Number of Products by Stage and Mechanism of Actions, H2 2019
  • Figure 8: Number of Products by Routes of Administration, H2 2019
  • Figure 9: Number of Products by Stage and Routes of Administration, H2 2019
  • Figure 10: Number of Products by Molecule Types, H2 2019
  • Figure 11: Number of Products by Stage and Molecule Types, H2 2019
目次
Product Code: GMDHC11565IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Primary Immune Deficiency (PID) - Pipeline Review, H2 2019, provides an overview of the Primary Immune Deficiency (PID) (Genetic Disorders) pipeline landscape.

Primary immunodeficiency is defined as weaken immune system, allowing repeated infections and other health problems to occur more easily. Signs and symptoms include blood infections, pneumonia, bronchitis, sinus infections, ear infections, meningitis or skin infections, digestive problems, such as cramping, loss of appetite, nausea and diarrhea.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Primary Immune Deficiency (PID) - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Primary Immune Deficiency (PID) (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Primary Immune Deficiency (PID) (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Primary Immune Deficiency (PID) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II and Preclinical stages are 1, 9, 3 and 9 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 10, 1 and 3 molecules, respectively.

Primary Immune Deficiency (PID) (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Primary Immune Deficiency (PID) (Genetic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Primary Immune Deficiency (PID) (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Primary Immune Deficiency (PID) (Genetic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Primary Immune Deficiency (PID) (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Primary Immune Deficiency (PID) (Genetic Disorders)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Primary Immune Deficiency (PID) (Genetic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Primary Immune Deficiency (PID) (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • List of Tables
  • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Primary Immune Deficiency (PID) - Overview
  • Primary Immune Deficiency (PID) - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Primary Immune Deficiency (PID) - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Primary Immune Deficiency (PID) - Companies Involved in Therapeutics Development
    • ADMA Biologics Inc
    • AlloVir Inc
    • Biotest AG
    • Cellective BioTherapy Inc
    • Clinigen Group Plc
    • Enzyvant Sciences Ltd
    • Evolve Biologics Inc
    • GC Pharma
    • GigaGen Inc
    • Grifols SA
    • Liminal BioSciences Inc
    • Mustang Bio Inc
    • Octapharma AG
    • Orchard Therapeutics Plc
    • Rocket Pharmaceuticals Inc
    • Sangamo Therapeutics Inc
    • Taiga Biotechnologies Inc
    • Takeda Pharmaceutical Co Ltd
    • X4 Pharmaceuticals Inc
  • Primary Immune Deficiency (PID) - Drug Profiles
    • aldesleukin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ALVR-105 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Antibody for Primary Immune Deficiency Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Biologic 1 for Genetic Disorders and Infectious Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Biologic for Genetic Disorders and Infectious Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BT-595 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cellular Immunotherapy for Severe Combined Immune Deficiency and Graft Versus Host Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy for RAG-Deficient Severe Combined Immune Deficiency - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy for X-Linked SCID - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy to Activate Adenosine Deaminase for Adenosine Deaminase Deficiency Related SCID - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy to Activate Adenosine Deaminase for Severe Combined Immune Deficiency - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy to Activate Artemis for Severe Combined Immune Deficiency - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy to Activate Artemis for Severe Combined Immunodeficiency - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy to Activate IL-2 Gamma Receptor for SCID-X1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy to Activate IL-2 Gamma Receptor for X-Linked SCID - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy to Activate IL2RG for SCID-X1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy to Activate IL2RG for X-Linked SCID - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • hyaluronidase (recombinant, human) + immune globulin (human) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • immune globulin (human) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • immune globulin (human) 2 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • mavorixafor - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MB-107 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RPL-201 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RVT-802 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • simoladagene autotemcel - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit CXCL12 for WHIM Syndrome - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Strimvelis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TBX-1400 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • X-4P003 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Primary Immune Deficiency (PID) - Dormant Projects
  • Primary Immune Deficiency (PID) - Discontinued Products
  • Primary Immune Deficiency (PID) - Product Development Milestones
    • Featured News & Press Releases
      • Nov 12, 2019: X4 Pharmaceuticals receives Breakthrough Therapy Designation from the FDA for Mavorixafor for the treatment of WHIM syndrome
      • Oct 15, 2019: Rocket Pharmaceuticals announces upcoming presentation on RPL-201 at the European Society of Gene and Cell Therapy Annual Congress
      • Sep 06, 2019: Rocket Pharmaceuticals begins gene therapy in LAD-I study
      • Aug 12, 2019: Kedrion Biopharma announces first patient enrolled in CARES10, a phase 3, multi-center study to assess a 10 percent intravenous immunoglobulin in adults with primary immunodeficiency disease
      • Jul 30, 2019: X4 Pharmaceuticals receives orphan drug designation from European Commission for Mavorixafor for treatment of WHIM syndrome
      • Jul 05, 2019: FDA approves Grifols' Xembify for immunodeficiencies
      • Jun 26, 2019: X4 Pharmaceuticals initiates pivotal phase 3 clinical trial of Mavorixafor for the treatment of WHIM Syndrome
      • Apr 01, 2019: X4 Pharmaceuticals provides business and clinical development update
      • Dec 01, 2018: X4 Pharmaceuticals presents additional positive phase 2 results for X4P-001 in WHIM syndrome, continues on path to initiation of phase 3 trial
      • Nov 06, 2018: X4 Pharmaceuticals presents clinical data demonstrating single agent X4P-001-IO enhances tumor immunity through CXCR4 antagonism
      • Nov 01, 2018: X4 Pharmaceuticals to present clinical data used to determine phase 3 dose from phase 2/3 study of X4P-001-RD in WHIM syndrome
      • Oct 26, 2018: GigaGen to present data on Recombinant Hyperimmune Gammaglobulin at the 18th Biennial Meeting of the European Society for Immunodeficiencies
      • Oct 15, 2018: X4 Pharmaceuticals receives orphan drug designation from the U.S. FDA for X4P-001-RD for the treatment of WHIM syndrome
      • Sep 25, 2018: Evolve Biologics provides update on progress in phase III trial for PlasmaCap IG (Intravenous Immunoglobulin)
      • Jun 15, 2018: X4 Presents Data from Ongoing Phase 2 Study Demonstrating Promising Activity of X4P-001-RD in Patients with WHIM Syndrome
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer
Back to Top